Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
Results Patient characteristics All 15 participants were female, and randomly assigned to receive either exenatide (n = 7) or placebo (n = 8)
Friends I had not seen in a while commented that I looked younger
Neuroinflammation, oxidative stress and the pathogenesis of Parkinsons disease
Temporal plot of the tri-peptides cystine (cys), glutamate (glut) and glycine (gly) and glutamyl-cysteine (glucys) along with changes in gsh and gssg
Toxicology of nanoparticles: a historical perspective